Donga Socio Holdings - Asset Resilience Ratio
Donga Socio Holdings (000640) has an Asset Resilience Ratio of 1.85% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 000640 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Donga Socio Holdings's Asset Resilience Ratio has changed over time. See 000640 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Donga Socio Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Donga Socio Holdings worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩37.95 Billion | 1.85% |
| Total Liquid Assets | ₩37.95 Billion | 1.85% |
Asset Resilience Insights
- Limited Liquidity: Donga Socio Holdings maintains only 1.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Donga Socio Holdings Industry Peers by Asset Resilience Ratio
Compare Donga Socio Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Donga Socio Holdings (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Donga Socio Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | ₩9.95 Billion ≈ $6.75 Million |
₩2.03 Trillion ≈ $1.38 Billion |
-1.59pp |
| 2023-12-31 | 2.08% | ₩40.64 Billion ≈ $27.54 Million |
₩1.96 Trillion ≈ $1.33 Billion |
+1.46pp |
| 2022-12-31 | 0.61% | ₩10.63 Billion ≈ $7.20 Million |
₩1.73 Trillion ≈ $1.17 Billion |
-2.86pp |
| 2021-12-31 | 3.48% | ₩58.84 Billion ≈ $39.87 Million |
₩1.69 Trillion ≈ $1.15 Billion |
-0.21pp |
| 2020-12-31 | 3.68% | ₩55.67 Billion ≈ $37.73 Million |
₩1.51 Trillion ≈ $1.02 Billion |
-0.35pp |
| 2019-12-31 | 4.03% | ₩54.81 Billion ≈ $37.14 Million |
₩1.36 Trillion ≈ $920.69 Million |
+3.56pp |
| 2018-12-31 | 0.48% | ₩5.93 Billion ≈ $4.02 Million |
₩1.24 Trillion ≈ $841.64 Million |
+0.40pp |
| 2017-12-31 | 0.08% | ₩1.11 Billion ≈ $749.55K |
₩1.46 Trillion ≈ $989.05 Million |
-0.10pp |
| 2016-12-31 | 0.17% | ₩2.43 Billion ≈ $1.65 Million |
₩1.40 Trillion ≈ $950.26 Million |
-0.13pp |
| 2015-12-31 | 0.30% | ₩3.70 Billion ≈ $2.51 Million |
₩1.22 Trillion ≈ $829.16 Million |
+0.09pp |
| 2014-12-31 | 0.21% | ₩2.25 Billion ≈ $1.52 Million |
₩1.08 Trillion ≈ $732.63 Million |
-0.52pp |
| 2013-12-31 | 0.73% | ₩7.20 Billion ≈ $4.88 Million |
₩988.28 Billion ≈ $669.74 Million |
+0.52pp |
| 2012-12-31 | 0.21% | ₩3.59 Billion ≈ $2.43 Million |
₩1.72 Trillion ≈ $1.17 Billion |
-2.77pp |
| 2011-12-31 | 2.98% | ₩44.45 Billion ≈ $30.12 Million |
₩1.49 Trillion ≈ $1.01 Billion |
+2.16pp |
| 2010-12-31 | 0.82% | ₩10.09 Billion ≈ $6.84 Million |
₩1.23 Trillion ≈ $836.45 Million |
+0.66pp |
| 2009-12-31 | 0.16% | ₩1.69 Billion ≈ $1.14 Million |
₩1.06 Trillion ≈ $716.50 Million |
-0.43pp |
| 2008-12-31 | 0.59% | ₩4.52 Billion ≈ $3.06 Million |
₩769.94 Billion ≈ $521.78 Million |
-0.37pp |
| 2007-12-31 | 0.96% | ₩6.83 Billion ≈ $4.63 Million |
₩713.72 Billion ≈ $483.68 Million |
+0.05pp |
| 2006-12-31 | 0.91% | ₩6.62 Billion ≈ $4.49 Million |
₩731.74 Billion ≈ $495.89 Million |
-0.35pp |
| 2005-12-31 | 1.25% | ₩9.08 Billion ≈ $6.15 Million |
₩724.29 Billion ≈ $490.84 Million |
+0.04pp |
| 2004-12-31 | 1.21% | ₩8.56 Billion ≈ $5.80 Million |
₩706.01 Billion ≈ $478.45 Million |
-1.10pp |
| 2003-12-31 | 2.31% | ₩15.98 Billion ≈ $10.83 Million |
₩691.41 Billion ≈ $468.56 Million |
+0.08pp |
| 2002-12-31 | 2.23% | ₩13.18 Billion ≈ $8.93 Million |
₩590.72 Billion ≈ $400.32 Million |
-2.21pp |
| 2001-12-31 | 4.44% | ₩26.35 Billion ≈ $17.86 Million |
₩593.63 Billion ≈ $402.30 Million |
+0.49pp |
| 2000-12-31 | 3.95% | ₩21.63 Billion ≈ $14.66 Million |
₩547.36 Billion ≈ $370.94 Million |
-- |
About Donga Socio Holdings
Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of S… Read more